PeerVoice Internal Medicine Audio

Jonathan Barratt, PhD, FRCP - From Mechanisms to Action: Exploring the Therapeutic Potential of Complement Inhibition in IgA Nephropathy

Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can

Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

Ashkan Shoamanesh, MD, FRCPC - Turning Pathophysiologic Promise Into Evidence-Based Potential: Are Factor XIa Inhibitors Ready for Prime Time in Secondary Stroke Prevention?

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases

Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients

Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management

Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders?

Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities

Jörn M. Schattenberg, MD - Cases in Contemporary MASH Management: Expert Insights on the Practical Integration of Disease-Specific Pharmacotherapy

Naim Alkhouri, MD, FAASLD, DABOM - Don’t Wait, and Look Beyond Weight: The Growing Case for Urgent and Comprehensive Management of MASH

Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target

Kris V. Kowdley, MD - Advancing the Management of Cholestatic Liver Disease: Optimizing Treatment Pathways and Novel Therapies

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: Breaking Down the Data Driving Therapeutic Developments in IgA Nephropathy

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition

Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring?

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: A Fresh Look at the Data Driving Targeted Therapeutic Developments in IgA Nephropathy

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

Nancy Carteron, MD, FACR - Congress Insights Direct From Chicago: The Need-to-Knows on B Cell–Targeting in Sjögren’s Disease

Mike Sharma, MD, MSc, FRCPC - Challenging the Status Quo in Secondary Stroke Prevention: Current Perspectives on the Potential of Factor XIa Inhibition

David Alain Wohl, MD - Inpatient Management of SARS-CoV-2 Infection: Applying Learnings From Real World Evidence to Real World Practice

Francesco Cappelli, MD, PhD - Meaningful Data From Madrid: Expanding Our Understanding of Phase 3s and OLEs in ATTR-CM

Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025